

Subject:	Research and Development Quarterly Update Q2 2019/20	Date: 3rd October 2019		
Prepared By:	Alison Steel, Head of Research and Innovation			
Approved By:	David Hodgson, Research and Innovation Director			
Presented By:	Alison Steel, Head of Research and Innovation			
Purpose				
Summary of R&I metrics and benchmarking performance (Q4)		Decision		
Assurance of financial position at Q4		Approval		
Patient Experience		Assurance		X
Communication and Engagement				
Outline of 2019/20 Strategic Priorities				
Strategic Objectives				
To provide outstanding care to our patients	To support each other to do a great job	To inspire excellence	To get the most from our resources	To play a leading role in transforming health and care services
X		X	X	X
Overall Level of Assurance				
	Significant	Sufficient	Limited	None
		X		
Risks/Issues				
Financial	<ul style="list-style-type: none"> Confirmed £713,387.00 EMCRN budget, a small decrease of 0.2% on 18/19, excl NHS pay award Commercial income for re-investment £103,166.36 			
Patient Impact	305 participants took part in patient experience survey up to the end of Q2 19/20 with a satisfaction score of 89%			
Staff Impact	<ul style="list-style-type: none"> Currently appointing to the SFH Research academy Funding provided to support an ED and critical care nurse to assist with the delivery of research out of hours 			
Services				
Reputational	Currently have a strong reputation for research delivery across the region and have been praised for strengths in financial probity, overall recruitment and recruitment to time and target by the EMCRN.			
Committees/groups where this item has been presented before				
PSQG in September 2019				
Executive Summary				
Recruitment performance in Research and Innovation at SFH. Q2 performance 2019/20:				
1. 894 participants recruited in 19/20 c.f to 1242 in 18/19				

David

2. 69 studies are open at SFH with 55 actively recruiting
3. 100% of commercial and 80% of non-commercial studies are recruiting to 100% time and target
4. Trials are spread across most specialities in the organisation with more clinical research activity being conducted in the areas of Cancer, Cardiovascular disease, Gastroenterology, Reproductive Health and Childbirth and Stroke. New areas opening studies e.g , Critical Care and Emergency Department
5. Summary of research impacts and outputs at SFH over a 3 year period detailed in Appendix 1
6. **Dashboard provides visual display of Q2 KPI's and key data**